Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alcohol Dependence
Interventions: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1, Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
Interventions: Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T; Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seizures
Interventions: Oxcarbazepine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bioequivalence
Interventions: Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib capsule; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Glendale, California • Brooklyn, Maryland • Salt Lake City, Utah

Conditions: Prostate Cancer, Advanced Prostate Carcinoma
Interventions: Hyperpolarized C13, Magnetic Resonance Imaging (MRI); Drug · Procedure
Lead sponsor: Ivan de Kouchkovsky, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anesthesia
Interventions: Modified Time Principle Induction (MTPI) with rocuronium, RSI succinylcholine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more

Conditions: Breast Cancer
Interventions: D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Atrial Fibrillation, Obstructive Sleep Apnea
Interventions: Delayed enhancement magnetic resonance imaging (DE-MRI); Device
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: New Orleans, Louisiana

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Disease
Interventions: MR Fingerprinting; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gout, Hyperuricemia
Interventions: Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cigarette Smoking
Interventions: Market Price Condition (control), Tobacco Parity Tax Condition, Nicotine-Content Tax Condition, Harm-Reduction Tax Condition, Modified Risk Tobacco Product (MRTP) Tax Condition; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 21 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Buffalo, New York • Roanoke, Virginia

Conditions: HIV Infections
Interventions: tenofovir/BI 201335; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
Interventions: Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: ESCC
Interventions: Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based validation (SYNERGY assay); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Lymphoma
Interventions: Platelet Transfusion; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pharmacokinetics
Interventions: DS-8500a, Itraconazole; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteer
Interventions: GSK1349572, Placebo, Omeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

Spectroscopy With Surface Coils and Decoupling

Study of Prostate Cancer in Black and White U.S. Veterans

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Novel MRI Sequence- MR Fingerprinting

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

The Impact of Innovative Tax Proposals on Purchase Patterns

Drug Drug Interaction of BI 201335 and Tenofovir

Regional Phenotyping of CF and Non-CF Bronchiectasis

Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects

A Study of LY2484595 in Healthy Subjects

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study